NORML Foundation NEWS ALERT
1001 Connecticut Ave., NW Ste. 710
Washington, DC 20036
202-483-8751 (p) 202-483-0057 (f)
www.norml.org
foundation@norml.orgOctober 27, 1998
Synthetic THC Fails To Provide Relief For Some Patients, New NORML Report Finds
Washington, D.C.: The availability of synthetic THC should not preclude patients from
legally using marijuana as a medicine, concluded a report released by the NORML
Foundation.
Synthetic THC, marketed as the drug Marinol, "often provides only limited relief
to a select group of patients, particularly when compared to whole smoked marijuana
therapy," the report found. "Marinol should remain an option for patients and
physicians; however, federal law should be reformed to allow for those patients
unresponsive to synthetic THC the opportunity to use inhaled marijuana as a legal medical
therapy."
The report states, "The active ingredient in Marinol,
delta-9-tetrahydrocannabinol, is only one of the compounds isolated in marijuana known to
have medical benefit to patients." For example, research published this summer in the
Proceedings of the National Academy of Sciences demonstrated that additional compounds
found naturally in marijuana, but unavailable in Marinol, appear to protect brain cells
during head trauma and strokes. Head injuries are the leading cause of death among young
people in America, and there presently are few if any effective treatments for such
traumas.
"By federally prohibiting the consumption of whole smoked marijuana, the
government unnecessarily forces patients to use a synthetic substitute that lacks much of
the therapeutic effectiveness marijuana provides," said Allen St. Pierre, executive
director of The NORML Foundation.
The Food and Drug Administration approved Marinol in 1985. DEA policy advises
physicians to prescribe Marinol only to patients undergoing cancer chemotherapy or
suffering from the AIDS wasting syndrome. Medical research demonstrates that marijuana is
therapeutic in the treatment of several additional illnesses such as glaucoma, multiple
sclerosis and chronic pain.
Many patients who have tried Marinol report that they find minimal relief from the drug
and often experience unwanted side effects. In addition, many physicians have difficulty
prescribing the drug, and some patients are unable to afford it. In a series of
state-sponsored studies conducted in the 1980s, patients offered a choice between using
oral THC or whole smoked marijuana as a medicine almost all reported finding greater
medical relief from marijuana.
The report is now available online at: www.norml.org/medical/marinol.html.